Cingulate Therapeutics: Cingulate raises $7.5m for controlled-release ADHD therapy

Cingulate Therapeutics said today that it landed a $7.5 million investment to help fund the development of its controlled-release ADHD drugs. The Kansas City-based company is working on a set of therapies that utilize its 'Precision Time Release' drug-delivery platform. Cingulate's CEO, Shane Schaffer, told Drug Delivery Business News that his company set out to create an ADHD therapy that tackles all [...]The post Cingulate raises $7.5m for controlled-release ADHD therapy appeared first on MassDevice.